Title of Invention

"1-(AMINOALKYL)-3-SULFONYLAZAINDOLE COMPOUNDS

Abstract The present invention provides a compound of formula (I) and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
Full Text 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES-AS COMPOUNDS
This invention relates to 1-(aminoalkyl)-3-suffonylazaindoles useful as 5-
hydroxytryptamine-6 ligands, to processes for preparing them, to methods of
treatment using them and to pharmaceutical compositions containing them.
BACKGROUND OF THE INVENTION
Serotonin (5-Hydroxytryptamine)(5-HT) receptors play a critical role in many
physiological and behavioral functions in humans and animals. These functions are
mediated through various 5-HT receptors distributed throughout the body. There are
now approximately fifteen different human 5-HT receptor subtypes that have been
cloned, many with well-defined roles in humans. One of the most recently identified
5-HT receptor subtypes is the 5-HT6 receptor, first cloned from rat tissue in 1993
(Monsma, F. J.; Shen, Y.; Ward, R. P.; Hambiin, M. W. Molecular Pharmacology
1993, 43, 320-327) and subsequently from human tissue (Kohen, R.; Metcalf, M. A.;
Khan, N.; Druck, T.; Huebner, K.; Sibley, D. R. Journal of Neurochemistry 1996, 66,
47-56). The receptor is a G-protein coupled receptor (GPCR) positively coupled to
adenylate cyclase (Ruat, M.; Traiffort, E.; Arrang, J-M.; Tardivel-Lacombe, L; Diaz,
L; Leurs, R.; Schwartz, J-C. Biochemical Biophysical Research Communications
1993, 193, 268-276). The receptor is found almost exclusively in the central nervous
system (CNS) areas both in rat and in human. In situ hybridization studies of the
5-HT6 receptor in rat brain using mRNA indicate principal localization in the areas of
5-HT projection including striatum, nucleus accumbens, olfactory tubercle, and
hippocampal formation (Ward, R. P.; Hambiin, M. W.; Lachowicz, J. E.; Hoffman, B.
J.; Sibley, D. R.; Dorsa, D. M. Neuroscience 1995, 64, 1105-1111).
There are many potential therapeutic uses for 5-HT6 ligands in humans
based on direct effects and on indications from available scientific studies. These

studies include the localization of the receptor, the affinity of ligands with known in
vivo activity, and various animal studies conducted so far.
One potential therapeutic use of modulators of 5-HT6 receptor function is in
the enhancement of cognition and memory in human diseases such as
Alzheimer"sThe high levels of receptor found in important structures in the forebrain,
including the caudate/putamen, hippocampus, nucleus accumbens, and cortex
suggest a role for the receptor in memory and cognition since these areas are known
to play a vital role in memory (Gerard, C.; Martres, M.-P.; Lefevre, K.; Miquel, M.C.;
Verge, D.; Lanfumey, R.; Doucet, E.; Hamon, M.; El Mestikawy, S. Brain Research,
1997, 746, 207-219). The ability of known 5-HT6 receptor ligands to enhance
cholinergic transmission also supports the potential cognition use (Bentley, J. C.;
Boursson, A.; Boess, F. G.; Kone, F. C.; Marsden, C. A.; Petit, N.; Sleight, A. J.
British Journal of Pharmacology, 1999,126(7), 1537-1542). Studies have found that
a known 5-HT6 selective antagonist significantly increased glutamate and aspartate
levels in the frontal cortex without elevating levels of noradrenaline, dopamine, or 5-
HT. This selective elevation of neurochemicals known to be involved in memory and
cognition strongly suggests a role for 5-HT6 ligands in cognition (Dawson, L A.;
Nguyen, H. Q.; U, P. British Journal of Pharmacology, 2000,130(1), 23-26). Animal
studies of memory and learning with a known selective 5-HT6 antagonist found some
positive effects (Rogers, D. C; Hatcher, P. D.; Hagan, J. J. Society of Neurosdence,
Abstracts 2000,26,680).
A related potential therapeutic use for 5-HT6 ligands is the treatment of
attentionjdeficit disorders (ADD, also known as Attention Deficit Hyperactiyjty
Disorder or ADHD) in both children and adults. Because 5-HT6 antagonists appear
to enhance the activity of the nigrostriatal dopamine pathway and because ADHD
has been linked to abnormalities in the caudate (Ernst, M; Zametkin, A. J.; Matochik,
J. H.; Jons, P. A.; Cohen, R. M. Journal of Neurosdence 1998,18(15), 5901-5907),
5-HT6 antagonists may attenuate attention deficit disorders.
Early studies examining the affinity of various CNS ligands with known
therapeutic utility or a strong structural resemblance to known drugs suggests a role
for 5-HT6 ligands in the treatment of schizophrenia and depression. For example,
clozapine (an effective clinical antipsychotic) has high affinity for the 5-HT6 receptor
subtype. Also, several clinical antidepressants have high affinity for the receptor as

well and act as antagonists at this site (Branchek, T. A.; Blackburn, T. P. Annual
Reviews in Pharmacology and Toxicology 2000, 40, 319-334).
Further, recent in vivo studies in rats indicate 5-HT6 modulators may be
useful in the treatment of movement disorders including epilepsy (Stean, T.;
Routledge, C; Upton, N. British Journal of Pharmaco/ogy 1999,127 Proc.
Supplement 131P and Routledge, C.; Bromidge, S. M.; Moss, S. F.; Price, G. W.;
Hirst, W.; Newman, H.; Riley, G.; Gager, T.; Stean, T.; Upton, N.; Clarke, S. E.;
Brown, A. M. British Journal of Pharmacology 2000, 130(7), 1606-1612).
Taken together, the above studies strongly suggest that compounds which are
5-HT6 receptor ligands may be useful for therapeutic indications including: the
treatment of diseases associated with a deficit in memory, cognition, and learning
such as Alzheimer"s and attention deficit disorder; the treatment of personality
disorders such as schizophrenia; the treatment of behavioral disorders, e.g., anxiety,
depression and obsessive compulsive disorders; the treatment of motion or motor
disorders such as Parkinson"s disease and epilepsy; the treatment of diseases
associated with neurodegeneration such as stroke and head trauma; or withdrawal
from drug addiction including addiction to nicotine, alcohol, and other substances of
abuse.
Therefore, it is an object of this invention to provide compounds which are
useful as therapeutic agents in the treatment of a variety of central nervous system
disorders related to or affected by the 5-HT6 receptor.
It is another object of this invention to provide therapeutic methods and
pharmaceutical compositions useful for the treatment of central nervous system
disorders related to or affected by the 5-HT6 receptor.
It is a feature of this invention that the compounds provided may also be used
to further study and elucidate the 5-HT6 receptor.
These and other objects and features of the invention will become more
apparent by the detailed description set forth hereinbelow.
SUMMARY OF THE INVENTION
The present invention provides a 1-(aminoalkyl)-3-sulfonylazaindole
derivative of formula I


wherein
W is N or CR7;
X is N or CR8;
Y is N or CR9;
Z is N or CR10 with the proviso that at least one and no more than two of W,
X, Yand Z must be N;
n is an integer of 2, 3, 4 or 5;
R1 is an optionally substituted C1-C8alkyl, C3C7cycloalkyl, aryl, or heteroaryl
group or an optionally substituted 8- to 13-membered bicyclic ortricyclic
ring system having a N atom at the bridgehead and optionally containing
1, 2 or 3 additional heteroatoms selected from N, O or S;
R2 is H, halogen, or a C1-C8alkyl, C1-C6alkoxy, C3-C7cycloalkyl, aryl or
heteroaryi group each optionally substituted;
R3 and R4 are each independently H or an optionally substituted C1-C6alkyl
group;
R5 and R6 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-
C6alkynyl, C3-C7cycloalkyl, cydoheteroalkyl, aryl or heteroaryi group
each optionally substituted , or R6 and R6 may be taken together with
the atom to which they are attached to form an optionally substituted
5- to 8-membered ring optionally containing an additional heteroatom
selected from O, NR11 or SOm;
R7, Rs, RB and R10 are independently H, halogen, CN, OCO2R12, CO2R13,
CONR14R15, SOPR16, NR17R18, OR19, COR20, or a C1-C6alkyl, C2-
Csalkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or
heteroaryi group each optionally substituted;
R11, R12, R13, R16, R19 and R20 are each independently H or a C1-C5alkyl, C2-
Cealkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or
heteroaryi group each optionally substituted;

R14 and R15 are each independently H or an optionally substituted C1-C6alkyl
group or R14 and R15 may be taken together with the atom to which
they are attached to form a 5- to 7-membered ring optionally
containing another heteroatom selected from O, NR22 or S;
R17 and R18 are each independently H or an optionally substituted C1-C4alkyl
group or R17 and R18 may be taken together with the atom to which
they are attached to form a 5- to 7-membered ring optionally
containing another heteroatom selected from O, NRa or SOx;
R21 and R22 are each independently H or a C1-C6alkyi, C2-C6alkenyl, C3-
C7cycloalkyl, cycloheteroalkyl, aryl orheteroaryl group each optionally
substituted; and
m, p and x are each independently 0 or an integer of 1 or 2; or
a stereoisomer thereof or a pharmaceuticalfy acceptable salt thereof.
The present invention also provides methods and compositions useful for the
therapeutic treatment of central nervous system disorders related to or affected by
the 5-HT6 receptor.
DETAILED DESCRIPTION OF THE INVENTION
The 5-hydroxytryptamine-6 (5-HT6) receptor is one of the most recent
receptors to be identified by molecular cloning. Its ability to bind a wide range of
therapeutic compounds used in psychiatry, coupled with its intriguing distribution in
the brain has stimulated significant interest in new compounds which are capable of
interacting with or affecting said receptor. Significant efforts are being made to
understand the possible role of the 5-HT6 receptor in psychiatry, cognitive
dysfunction, motor function and control, memory, mood and the like. To that end,
compounds which demonstrate a binding affinity for the 5-HT6 receptor are earnestly
sought both as an aid in the study of the 5-HT6 receptor and as potential therapeutic
agents In the treatment of central nervous system disorders, for example see
C. Reavill and D. C. Rogers, Current Opinion in Investigational Drugs, 2001,
2(1 ):104-109, Pharma Press lid.
SurprisingJ^JMha§ now been found that 1-(aminc)alkyl)-3-sulfonyla2a|rjdiQle
derivatives of formula I demonstrate 5-HT6 affinity. Advantageously, said azaindole
derivatives may be used as effective therapeutic agents for the treatment of central
nervous system (CNS) disorders associated with or affected by the 5-HT6 receptor.

Accordingly, the present invention provides 1-(aminoalkyl)-3-sutfonylazaindole
derivatives of formula I

wherein
W is N or CR7;
X is N or CR8
Y is N or CR9;
Z is N or CR10 with the proviso that at least one and no more than two of W,
X, Y and Z must be N;
n is an integer of 2, 3, 4 or 5;
R1 is an optionally substituted C1-C6alkyI, C3-C7cycloalkyl, aryl, or heteroaryl
group or an optionally substituted 8- to 13-membered bicydic or tricyclic
ring system having a N atom at the bridgehead and optionally containing
1, 2 or 3 additional heteroatoms selected from N, O or S;
R2 is H, halogen, or a C1-C6alkyl, C1-C6aJkoxy, C3-C7cycloalkyl, aryl or
heteroaryl group each optionally substituted;
R3 and R4 are each independently H or an optionally substituted C1-C6alkyt
group;
Rs and Re are each independently H or a C1-C6alkyl, C2-C6alkenyl, Cr
C6alkynyl, C3-C7cycioalkyl, cycloheteroalkyl, aryl or heteroaryl group
each optionally substituted, or R5 and R6 may be taken together with
the atom to which they are attached to form an optionally substituted
5- to 8-membered ring optionally containing an additional heteroatom
selected from O, NRn or SOm;
R7, R8, R9 and R10 are independently H, halogen, CN, OCO2R12, CO2R13,
CONR14R15, SOpR16, NR17R18, OR19, COR20, or a C1-C6alkyl, C2-
Cealkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or
heteroaryl group each optionally substituted;

R11, R12, R13, R16, R19 and R20 are each independently H or a C1-C6alkyl, C2-
C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or
heteroaryl group each optionally substituted;
R14 and R15 are each independently H or an optionally substituted V1-C6ealkyl
group or R14 and R15 may be taken together with the atom to which
they are attached to form a 5- to 7-membered ring optionally
containing another heteroatom selected from O, NR& or S;
R17 and R18 are each independently H or an optionally substituted C1-C4alkyl
group or R17 and R18 may be taken together with the atom to which
they are attached to form a 5- to 7-membered ring optionally
containing another heteroatom selected from O, NR21 or SOx;
R21 and R22 are each independently H or a V1-C6alkyl, V2-C6alkenyl, C3-
C7cycloalkyl, cycloheteroalkyl, aiyl or heteroaryl group each optionally
substituted; and
m, p and x are each independently 0 or an integer of 1 or 2; or
a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
As used in the specification and claims, the term halogen designates F, Cl, Br
or I and the term cycloheteroalkyl designates a 5-7 membered ring system containing
1 or 2 heteroatoms, which may be the same or different, selected from nitrogen,
oxygen and sulfur and optionally containing one double bond. Exemplary of the
cycloheteroalkyl ring systems included in the term as designated herein are the
following rings wherein X1 is NR, O or S; and R is H or an optional substituent as
described hereinbelow:

Similarly, as used in the specification and claims, the term heteroaryl
designates a five to ten membered aromatic ring system containing 1, 2 or 3
heteroatoms, which may be the same or different, selected from N, O or S. Such
heteroaryl ring systems include pyrrofyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furyl,

thienyl, quinolinyl, isoquinolinyl, indolinyl, benzothienyl, benzofuranyl, benzisoxazolyl
or the like. The term aryt designates a carbocyclic aromatic ring system, e.g., having
6-14 carbon atoms such as phenyl, naphthyl, anthracenyi or the like. The term
haloalkyi as used herein designates a CnHam group having from one to 2n+1
halogen atoms which may be the same or different and the term haloalkoxy as used
herein designates an OCnHani group having from one to 2n+1 halogen atoms which
may be the same or different
Exemplary of the 8- to 13-membered bicyclic or tricyclic ring systems having a
N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms
selected from N, O or S included in the term as designated herein are the following
ring systems wherein W2 is NR, O or S; and R is H or an optional subsfrtuent as
described hereinbelow:


In the specification and claims, when terms such as V1-C6alkyl, C2-C6alkenyl,
C2-C6alkynyl, C3-C7cydoalkyl, cydoheteroalkyj, aryl or heteroaryl are designated as
being optionally substituted, the substituent groups which are optionally present may
be one or more, e.g., 2 or 3, of those customarily employed in the development of
pharmaceutical compounds or the modification of such compounds to influence their
structure/activity, persistence, absorption, stability or other beneficial property.
Specific examples of such substituents include halogen atoms, nitro, cyano, hydroxyl,
alkyi, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl,
alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsuphinyl, alkyisulphonyl, carbamoyl,
alkylamldo, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl (such as heteroaryl or
cycloheteroalkyl) or cycloalkyl groups, preferably halogen atoms or lower alkyl
groups. Typically, 0-3 substituents may be present. When any of the foregoing
substituents represents or contains an alkyl substituent as a group or part of a group,
this may be linear or branched and may contain up to 12, preferably up to 6, more
preferably up to 4 carbon atoms.
Pharmaceutically acceptable salts may be any acid addition salt formed by a
compound of formula I and a pharmaceutically acceptable add such as phosphoric,
sulfuric, hydrochloric, hydrobromic, citric, maleic, malonic, mandelic, succinic,
fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the
like.
Compounds of the invention include esters, carbamates or other conventional
prodrug forms, which in general, are functional derivatives of the compounds of the
invention and which are readily converted to the inventive active moiety in vivo.
Correspondingly, the method of the invention embraces the treatment of the various
conditions described hereinabove with a compound of formula I or with a compound
which is not specifically disclosed but which, upon administration, converts to a
compound of formula I in vivo. Also included are metabolites of the compounds of
the present invention defined as active species produced upon introduction of these
compounds into a biological system.
Compounds of the invention may exist as one or more stereoisomers. The
various stereoisomers include enantiomers, diastereomers, atropisomers and
geometric isomers. One skilled in the art will appreciate that one stereoisomer may
be more active or may exhibit beneficial effects when enriched relative to the other

stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the
skilled artisan knows how to separate, enrich or selectively prepare said
stereoisomers. Accordingly, the present invention comprises compounds of Formula
1, the stereoisomers thereof and the pharmaceutically acceptable salts thereof. The
compounds of the invention may be present as a mixture of stereoisomers, individual
stereoisomers, or as an optically active or enantiomerically pure form.
Preferred compounds of the invention are those compounds of formula I
wherein W or Z is N. Also preferred are those compounds of formula I wherein n is
2. Another group of preferred compounds of formula I are those compounds wherein
Ri is an optionally substituted phenvl, naphthvl or imidazothiazolyl group.
More preferred compounds of the invention are those formula I compounds
wherein W is CIV, X is OFfe; Y is CIV, and Z is N. Another group of more preferred
compounds are those formula I compounds wherein W is N; X is CR8 Y is CR9 and Z
is CR10. More preferred compounds of formula I also include those compounds
wherein n is 2 and Ra and R4 are H. Further, more preferred compounds are those
formula I compounds wherein W or Z is N; n is 2; R1 is an optionally substituted
phenyl, naphthvl or imidazothiazolyl group; R2, R3 and R4 are H; and Rs and Re are
each independently H or Ci-Caalkyl.
Examples of preferred compounds of the invention include:
2-[3-(phenyisutfony1)-1 H-pyrrolo{2,3-b]pyridin-1-yl]ethylamine;
2-[3-(phenyisulfonyl)-1 H-pyrrolo[2,3-c]pyridin-1-yQethyiamine;
2-[3-(phenylsulfonyl)-1 H-pynolo[3,2-c]pyridin-1 -yQethylamine;
2-{3-[(4-fluorophenyl)sulfonyQ-1 H-pyrrolo[3,2-b]pyridin-1 -yQethylamine;
2-[3-{(4-methylphenyl)sulfonyl]-1 H-pyrrolo[2,3-b]pyridin-1 -yQethylamine;
2-[3-(naphth-1 -yl)suHonyl)-1 H-pyrrolo[2,3-b]pyiidin-1 -yQethylamine;
2-{3-[(6-chloro-imidazol2,1-b][1,3]thiazol-5-yl)sulfonyl]-1 H-pyrrolo[2,3-b]pyridin-1 -
yl}ethylamine;
2-{3-[(3-chlorophenyl)sulfonyl]-1 H-pyrroto[2t3-b]pyricnn-1 -yl}ethylamine;
2-{3-[(2-chlorophenyl)sulfonyQ-1 H-pyrrolo[2,3-c]pyridin-1 -yijethyiamine;
2-{3-t(3-methoxyphenyl)sulfonylJ-1 H-pyrrolo[3,2-c]pyridin-1 -yl}ethylamine;
2-{3-{(4-f luorophenyl)sulfonyl]-1 H-pyrrolo[3,2-b]pyridin-1 -yQethylamine;
N,N-dimethyl-N-(2-{3-[(3-fluorophenyl)sulfonyll-1 H-pyrrolo[2,3-b]pyridin-1 -
yl}ethyl)amine;

N,N-dimethyl-N-{2-[3-(naphth-1-ylsulfonyl)-1H-pyrrolo[2,3-b]pyriclin-1-yl]ethyl}amine;
N,N-dimethyl-N-(2-{3-[(6-chloroimida2o[1,2-b][1,3]thiazol-5-yl)sulfonyO-1H-
pyrrolo[2,3-b]pyridin-1-yl}ethyl)amine;
N,N-dimethyl-N-(2-{3-[(3-chlorophenyI)sulfonyl]-1 H-pyrrolo[2,3-b]pyridine-1 -
yl}ethyl)amine;
3-[3-(phenyisulfonyl)-1 H-pyrrolo[2,3-b]pyridin-1 -yl]propan-1 -amine;
3-[3-(phenyisulfony1)-1 H-pyrrolo[2,3-c]pyridin-1 -yl]propan-1 -amine;
3-[3-(phenylsulfonyl)-1 H-pyrrolo[3,2-c]pyridin-1 -yl]propan-1 -amine;
3-{3-[(4-fluorophenyl)sulfonyl]-1 H-pyrrolo[3,2-b]pyridin-1 -yl}propan-1 -amine;
2-{6-chloro-3-[(3-chlorophenyl)sulfonyq-1 H-pyrrolo[2,3-b]pyridin-1 -yl}ethylamine;
2-{7-chloro-3-t(2-chlorDphenyl)sulfonyt]-1 H-pyrrok>[2,3-c]pyridin-1-yl]ethyiamine;
4-{3-[(3-methoxyphenyl)sulfonyl]-1 H-pyrrok>[3,2-c]pyridin-1-yl}butan-1 -amine;
4-{3-{(4-fluorophenyl)sulfonyl]-1 H-pyrrolo[3,2-b]pyridin-1-yl}butan-i -amine;
N,N-dimethyt-N-{2-[3-(phenylsulfonyl)-1 H-pyrrok)[2l3-c]pyridin-1-yl]ethyl}amine;
N,N-dimethy)-N-{2-[3-(phenylsutfonyl)-1 H-pyrrolo[3,2-c]pyridin-1-yl]ethyl]amine;
N,N-dimethyl-N-{2-[3-(thien-2-yl)-1 H-pyrrolo[2,3-b]pyridin-1-yl]ethyl}amine;
N,N-dimethyl-N-{2-[3-(naphth-1 -yl)-1 H-pynrok)[2>3-b]pyridin-1 -yl]ethyl}amine;
N,N-dimethyi-N-(2-{3-[(4-fluorophenyl)sutfonyri-1 H-pyrrolo[3,2-b]pyridin-1 -
yl}ethyl)amine;
N-methyl-N-(2-{3-[(3-chiorophenyl)sulfonyq-1 H-pyrrolo[2,3-b]pyridin-1 -yl}ethyl)amine;
N-rnethyhN-(243-[(3-fluorophenyt)sulfonyQ-1H-pyrrolo[2,3-b]pyridin-1-yl}ethyl)amine;
N-methyl-N-{2-[3-(naphth-1 -yisutfonyl)-1 H-pyrroto[2,3-b]pyriidin-1-yl]ethyl}amine;
N-methyl-N-(2-{3-[(6-chtoroimidazol1 ^-b][1,3lthiazol-5-yl)sulfonyl]-1 H-pyrrolo[2,3-
b]pyridin-1 -yl}ethyl)amine;
N-methyl-N-(2-{3-{(2-chtorophenyl)sulfonyQ-1 H-pyrrolo[2,3-c]pyridin-1-yl}ethyl)amine;
N-methyl-N-(2-{3-[(3-methoxyphenyl)sulfonyr|-1 H-pyrrolo[3,2-c]pyridin-1 -
yl}ethyl)amine;
N-benzyl-N-(2-{3-[(4-fluorophenyl)sulfonyl]-1H-pyrrolo[3,2-b]pyridin-1-yl}ethyI)amine;
N,N-dibenzyl-3-[3-(phenylsutf onyl)-1 H-pyrroIo[2,3-b]pyridin-1-yl]propan-1 -amine;
3-[3-(phenylsulfonyl)-1 H-pyrrolo[2,3-c]pyridin-1 -yi]propan-1-amine;
3-[3-(phenylsulfonyl)-1 H-pyrroio[3,2-c]pyridin-1 -yl]propan-1-amine;
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

This invention also provides processes for preparing a compound of formula I as
defined herein or a stereoisomer thereof, or a pharmaceutically acceptable salt
thereof, which processes comprise one of the following:
a) reacting a compound of formula II

wherein W, X, Y, 2, R1 and R2are as described hereinabove with a haloalkylamine of
formula III
Hal-(CR3R4)n-NRsRe
wherein Hal represents Cl, Br or I and R3, R4, R5, Re and n are as described
hereinabove in the presence of a base to give a compound of formula I;
or
b) reacting a compound of formula (V)

wherein W, X, Y, Z, Rt, R3, FU and n are as defined herein and Hal is a halogen, with
a compound of formula
HNRsRe

wherein R5 and Re are as defined herein to give a compound of formula I;
or
c) sulphonylating a compound of formula XVI:

wherein W, X, Y, Z, R3, R4, R5| Re and n are as defined herein, with a compound of
formula:
CISQA
wherein R1 is as defined herein to give a compound of formula I;
or
d) reducing a compound of formula XX:

wherein W, X, Y, Z, Ri, R3, R4 and n are as defined herein, to give a corresponding
compound of formula I wherein Rs and Re are both hydrogen;
or
e) reacting a compound of formula


wherein W, X, Y, Z, Rlt R2, R3, R4, n and m are as defined herein.with hydrazine to
give a corresponding compound of formula I wherein R5 and Rs are both hydrogen;
or
f) converting a basic compound of formula I to a pharmaceutically
acceptable salt thereof or vice versa.
The compounds of the invention are conveniently prepared by processes
illustrated in the following flow diagrams wherein Hal represents Cl, Br or I.

Bases suitable for use in the process of the invention include strong bases
such as NaH, KOt-Bu, NaOH or any conventional base capable of removing a proton
from a basic azaindole nitrogen atom.
Solvents suitable for use in the process of the invention include polar solvents
such as dimethyl formamide, dimethyl sulfoxide, acetonitrile, tetrahydrofuran, or the
like. If two immiscible solvents are used, a phase transfer catalyst may be present
Preferably, for the preparation of those compounds of formula I wherein Rs and Re
are H, the compound of formula II may be reacted with a base as described
hereinabove in the presence of a phase transfer catalyst, such as
tetrabutylammonium hydrogensulfate, to give the desired compound of formula I
wherein Rs and Re are H.
Alternatively, compounds of formula I wherein R5and Ra are H (la) may be
prepared by reacting the formula II compound with a di-haloalkyl compound of
formula IV to give the 1-(haloalkyl)azaindole of formula V; reacting the formula V

azaindole with potassium phthalimide to give the intermediate of formula VI and
reacting said intermediate with hydrazine to give the desired formula la compound.
The reaction sequence is shown in flow diagram II wherein Hal represents Cl, Br or I.

Compounds of formula V may also be reacted directly with an amine,
HNRsRe, to give compounds of formula I. Compounds of formula II may be prepared
using conventional synthetic methods and, if required, standard separation and
isolation techniques. For example, a nitropyridine compound of formula VII may be
reacted with a chtorornethytsulfonyl compound of formula VIII in the presence of a
strong base to give the intermediate of formula IX; said formula IX intermediate may
then be treated with a reducing agent such as Fe, Zn or Sn in the presence of an
acid to give the amine of formula X; said amine may then be acylated with the
appropriate orthoester of formula XI to give the formula XII compound; and said
compound may be cyclized in the presence of a base to give the desired formula II3-

sulfonyl azaindole. The general synthetic method is described by W. Wojciechowski
and M. Makosza, Synthesis 1986,651-653. The reaction sequence is shown in flow
diagram III.

Compounds of formula II may also be prepared directly from an azaindole
compound, i.e. an azaindole of formula XIII may be reacted with iodine, optionally in
the presence of Kl, to give the corresponding 3-iodoazaindole of formula XIV and
said 3-iodoazaindole may be coupled with an appropriate thiol of formula XV to give
the 3-thioazaindole of formula XVI. Said formula XVI compound may then be
oxidized using conventional oxidizing reagents such as H2O2, m-chloroperbenzoic

acid or the like to afford the formula II intermediate. The reaction is shown in flow
diagram IV.

Alternatively, the formula XVI 3-thioazaindole intermediate may be prepared
in a single step from the azaindole of formula XIII by reacting said formula XIII
compound with the formula XV thiol in the presence of iodine, preferably in a polar
solvent such as aqueous alcohol. The thus-obtained formula II compounds may then
be earned on to the desired compounds of formula I by allegation of the basic
azaindole nitrogen as shown in flow diagrams I and II hereinabove.
Compounds of formula XIII may also be converted to the desired compounds
of formula I wherein Rs and Ffe are other than H (la) by reacting the formula XIII
azaindole with an amine of formula Ilia wherein R5 and Re are other than H to give
the N-alkylated compound of formula XVII; reacting the formula XVII compound with
a sulfonyl chloride of formula XVIII, optionally in the presence of a reagent such as

Ag(OSO2CF3) or Bi(OSO2CF3)3, to give the desired compound of formula la.
Similarly, compounds of formula I wherein R5 and Re are H (Ib) may be prepared
directly from the formula XIII intermediate by reacting said formula XIII intermediate
with a nitrile of formula XIX to give the corresponding alkylated compound of formula
XX; suffonylating said formula XX compound to give the compound of formula XXI;
and reducing the formula XXI compound using conventional reducing reagents such
as borane in tetrahydrofuran (THF) to give the desired compounds of formula Ib. The
reactions are shown in flow diagram V wherein Hal represents Cl, Br or I.


Advantageously, the formula I compounds of the invention are useful for the
treatment of CNS disorders relating or or affected by 5-HT6 receptor including motor,
mood, personality, behavioral, psychiatric, cognitive, neurodegenerative, or the like
disorders, for example Alzheimer"s disease, Parkinson"s disease, attention deficit
disorder, anxiety, epilepsy, depression, obsessive compulsive disorder, sleep
disorders, neurodegenerative disorders (such as head trauma or stroke), feeding
disorders (such as anorexia or bulimia), schizophrenia, memory loss, disorders
associated with withdrawal from drug or nicotine abuse, or the like or certain
gastrointestinal disorders such as irritable bowel syndrome. Accordingly, the present
invention provides a method for the treatment of a disorder of the central nervous
system related to or affected by the 5-HT6 receptor in a patient in need thereof which
comprises providing said patient a therapeutically effective amount of a compound of
formula I as described hereinabove. The compounds may be provided by oral or
parenteral administration or in any common manner known to be an effective
administration of a therapeutic agent to a patient in need thereof.
The term "providing" as used herein with respect to providing a compound or
substance embraced by the invention, designates either directly administering such a
compound or substance, or administering a prodrug, derivative or analog which
forms an equivalent amount of tha compound or substance within the body.
The therapeutically effective amount provided in the treatment of a specific
CNS disorder may vary according to the specific condition(s) being treated, the size,
age and response pattern of the patient, the severity of the disorder, the judgment of
the attending physician and the like. In general, effective amounts for dairy oral
administration may be about 0.01 to 1,000 mg/kg, preferably about 0.5 to 500 mg/kg
and effective amounts for parenteral administration may be about 0.1 to 100 mg/kg,
preferably about 0.5 to 50 mg/kg.
In actual practice, the compounds of the invention are provided by
administering the compound or a precursor thereof in a solid or liquid form, either
neat or in combination with one or more conventional pharmaceutical carriers or
excipients. Accordingly, the present invention provides a pharmaceutical
composition which comprises a pharmaceuticalfy acceptable carrier and an effective
amount of a compound of formula I as described hereinabove.

Solid carriers suitable for use in the composition of the invention include one
or more substances which may also act as flavoring agents, lubricants, solubilizers,
suspending agents, fillers, glidants, compression aides, binders, tablet-disintegrating
agents or encapsulating materials. In powders, the carrier may be a finely divided
solid which is in admixture with a finely divided compound of formula I. In tablets, the
formula I compound may be mixed with a carrier having the necessary compression
properties in suitable proportions and compacted in the shape and size desired. Said
powders and tablets may contain up to 99% by weight of the formula I compound.
Solid carriers suitable for use in the composition of the invention include calcium
phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin,
cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low
melting waxes and ion exchange resins.
Any pharmaceutjcally acceptable liquid carrier suitable for preparing
solutions, suspensions, emulsions, syrups and elixirs may be employed in the
composition of the invention. Compounds of formula I may be dissolved or
suspended in a pharmaceuticaHy acceptable liquid carrier such as water, an organic
solvent, or a pharmaceutically acceptable oil or fat, or a mixture thereof. Said liquid
composition may contain other suitable pharmaceutical additives such as
solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents,
suspending agents, thickening agents, coloring agents, viscosity regulators,
stabilizers, osmo-regulators, or the like. Examples of liquid earners suitable for oral
and parenteral administration include water (particularly containing additives as
above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose
solution), alcohols (including monohydric alcohols and potyhydric alcohols, e.g.,
glycols) or their derivatives, or oils (e.g., fractionated coconut oil and arachis oil). For
parenteral administration the carrier may also be an oily ester such as ethyl oteate or
isopropyl myristate.
Compositions of the invention which are sterile solutions or suspensions are
suitable for intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions
may also be administered intravenously. Inventive compositions suitable for oral
administration may be in either liquid or solid composition form.
For a more dear understanding, and in order to illustrate the invention more
dearly, specific examples thereof are set forth hereinbelow. The following examples

are merely illustrative and are not to be understood as limiting the scope and
underlying principles of the invention in any way.
The term HNMR designates proton nuclear magnetic resonance. The terms
CH2CI2 and DMF designate methylene chloride and dimethyl f ormamide,
respectively. All chrornatography is performed using SiO2 as support.

EXAMPLE 1
Preparation of 3-fPhenvlthioV-1H-pviTolor2.3-biDvridine

A solution of methyl phenyl sulfoxide (8.33 g, 59.4 mmol) in CH2CI2 is chilled
to -78°C and treated dropwise with trifluoroacetic anhydride (4.1 mL, 5.3 mmol).
After stirring for 30 min at -78°C, a solution of 7-azaindole (5.2 g, 44.0 mmol) in
CH2CI2 is added. After 30 min at -78°C, triethylamine (74 mL, 534 mmol) is added
and the reaction is allowed to reach ambient temperature. After stirring for 3.5 days,
the reaction is concentrated in vacuo, treated with saturated aqueous NaHCQj and
extracted with CH2CI2. The. organic extracts are combined and concentrated in
vacuo. The resultant residue is crystallized from methanoI/HjjO and recrystallized
from CHjjCla/hexane to afford the title compound as an off-white solid, 1.26 g, mp
188-189°C, characterized by mass spectral analyses and HNMR analyses.
EXAMPLE 2
Preparation of 3-fPhenvlsulfonvlV-1H-Dvrrolor2.3-biPvrldine

A solution of 3-(phenytthio)-1H-pyrrolo[2,3-b]pyridine (100 mg, 0.44 mmol) in
t-butyl alcohol is treated with MnSO4H2O (4 mg, 0.020 mmol) and cooled to 0°C. A
mixture of 30% aqueous hydrogen peroxide (500 mg, 4.41 mmol) and 02. N aqueous

NaHC03 (7.5 mL) is added dropwlse. The reaction is stirred for 23 h at 20°C. diluted
with saturated aqueous NaHCO3 and extracted with ethyl acetate. The combined
extracts are dried over MgSO4 and concentrated in vacuo. Chromatography (1:50
methanokCHsCIa) of the resultant residue yields a solid product which, is
recrystallized from CHsjCfc/hexane to afford the title compound as a pinkish-white
solid, 58 mg, mp > 250°C, characterized by mass spectral and HNMR analyses.
EXAMPLE 3
Preparation of W2-ChtoroethvlV3^Dhenv>sulfonvl>-1H-Dvrrolor2.3biPvrldlne

A solution of 3-(phenylsuKonyl)-1H-pyrrolo[2,3-b]pyridine (4.30 g, 16.6 mmol)
in 1,2-dichloroethane (33 ml_ 420 mmol) is treated with Aliquat®1 (6.9 g) and 50%
aqueous NaOH (1.6 g, 20 mmol). The reaction is stirred for 6 h at 45°C. The cooled
solution is diluted with H2O (200 mL) and extracted with CH2CI2 (3 x 250 mL). The
combined CH2CI2 extracts are dried over MgSO4 and concentrated in vacuo to a
brown gum. This gum is chromatographed (1:4 ethyl acetate:hexanes) and then
crystallized from ethyl acetate:hexanes to afford the title compound as a white solid,
3.84 g, mp 117-119°C, characterized by mass spectral and HNMR analyses.
1Tricapiylmethylarnmoniurn chloride, manufactured by Aldrich, Milwaukee, Wl

EXAMPLE 4
Preparation of 2-[2-[3-fPhenvlsulfonvlV1H-Dyrrolor[2,3-bi]yridlne-1-ynethyll]1 H-
isoindole-1.3(2H)-dione

A solution of 1-(2-chloroethyl)-3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
(3.84 g, 12.0 mmol) in DMF is treated with potassium phthalate (2.78 g, 15.0 mmol,
heated at 115°C for 16 h, cooled to room temperature, diluted with water and
extracted with ethyl acetate. The combined extracts are washed with brine, dried
over MgSO4 and concentrated in vacuo. The resultant residue is crystallized from
CH2Cl2/hexane to afford the title compound as a white solid, 4.54 g, characterized by
HNMR analysis.
Preparation of 2-T3-(Phenvlsulfonyl)-1H-pyrrolo[2,3-b]pyridinn-1-yl]ethylamine
dihydrochloride


A solution of 2-{2-[3-(phenylsuIfonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl]ethyl}-1H-
isoindole-1,3(2H)-dione (4.54 g, 10.5 mmol) in dioxane is treated with anhydrous
hydrazine (8.3 mL, 265 mmol), heated at 50°C for 3 h, concentrated in vacuo, diluted
with water and extracted with CH2CI2. The combined extracts are dried over MgSO4
and concentrated in vacuo to give a clear gum residue. Chromatography (1:9
methanol:CH2Cl2) of the residue affords the free amine of the title compound as a
clear gum. The free amine is dissolved in ethanol, acidified with 2N aqueous HCI.
and concentration in vacuo. Crystallization of the resultant residue from
ethanol/ether affords the title compound as a white solid, 3.20 g, mp 195-197°C,
characterized by mass spectral and HNMR analyses.
EXAMPLE 6
Preparation of N,N-Dimethyl-N-(2-[3-(phenylsurfonyl)-1H-pyrrolor[2,3-bipyridiln-
1-yl]ethyl]amine dlhydrochloride

A solution of 3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (400 mg, 1.55
mmol) in dry DMF is chilled to 0°C, treated with sodium hydride (60% in oil, 97 mg,
2.43 mmol), stirred for 3 h at 20°C, cooled to -20°C, treated with 2-(dimethylamino)-
ethyl chloride hydrochloride (336 mg, 2.33 mmol), stirred at 60°C for 16 h, cooled to
room temperature, quenched with water and extracted with ethyl acetate. The
organic extracts are combined, washed with brine, dried over MgSO4 and
concentrated in vacuo to afford the free amine of the title compound as a yellowish
gum. The gum is dissolved in ethanol, treated with 1N aqueous HCI and
concentrated in vacuo. Crystallization of the resultant residue from ethanol/ether

affords the title compound as a tight tan solid, 111 mg, mp 214-217°C, characterized
by mass spectral and HNMR analyses.
EXAMPLE 7
Preparation of 2-{3-[(4-Methylphenyl)sulfonyn-1H-pyrrolor[2,3-b]pyr[din-1-

Using essentially the same procedures described in Examples 1 through 6
hereinabove and employing 7-azaindole and methyl p-tolyl sulf oxide as starting
materials, the title product is obtained as a white solid, mp 215-217°C, characterized
by mass spectral and HNMR analyses.
Preparation of 3-lodo-1H-Pyrrolo[2,3-b]pyridine

A solution of 7-azaindole (20.0 g, 169 mmol) in ethanol is treated with iodine
(57.9 g, 228 mmol), potassium iodide (37.8 g, 228 mmol), and 1N aqueous NaOH
(204 mL, 204 mmol). After stirring for 4 h at 20°C, the reaction is diluted with water
and extracted with ethyl acetate. The organic extracts are combined and

concentrated in vacua The resultant residue is crystallized from methanoVwater to
afford the title compound as a pinkish-white solid, 35.4 g, mp 201-204°C,
characterized by mass spectral and HNMR analyses.
EXAMPLE 9
Preparation of 3-[(4-Ruorophenyl)thio]-1H-pyrrolor[2,3-b]pyridine

A solution of 3-iodo-1H-pyrroto[2,3-b]pyridine (4.0 g, 16.4 mmol) in DMF is
treated with 4-fluorobenzenethiof (2.09 mL, 19.7 mmol), potassium carbonate (3.40
g, 24.6 mmol), and copper iodide (4.21 g, 22.1 mmol). The reaction mixture is
heated at 65°C for 4 h, cooled, diluted with cone, aqueous NKUOH and extracted with
ethyl acetate. The extracts are combined, washed with brine, dried over MgSO4and
concentrated in vacua Chromatography (1:50 methanohCH2C2 of the residue,
followed by methanol/HjO crystallization affords the title compound as an off-white
solid, 3.56 g, mp 183-184°C, characterized by mass spectral and NMR analyses.
EXAMPLE 10
Preparation of 3-[(4-FluorophenylteuIfonyn-1H-pyrrolo[2,3-bi]pyridine


A solution of 3-[(4-fluorophenyl)thbl-1H-pyrro)o[2,3-b]pyridine (3.36 g, 13.8
mmol) in acetone is treated with a solution of NaHCO3 (2.90 g, 34.5 mmol) in water.
The reaction is then treated with Oxone*1 (25.5 g, 41.4 mmol), stirred for 3 h at 20°C,
diluted with water, cooled in an ice-water bath and filtered. The filtercake is washed
with water and vacuum dried to afford the title compound as a white solid 1.73 g, mp
212-213°C, characterized by mass spectral and NMR analyses.
12KHSO5- KHSO4 • K2SO4, manufactured by DuPont, Wilmington, DE.
EXAMPLE 11
vTVethvlamlne hvdrochiorlde

Using essentially the same procedure described in Examples 3 through 5
hereinabove and employing 3-[(4-fluorophenyl)sulfonyrj-1H-pyrrolo[2,3-b]pyridine as
substrate, the title product is obtained as a white solid, mp 193-197°C, characterized
by mass spectral and HNMR analyses.

EXAMPLE 12
Preparation of 2-{3-[(3-Chlorophenyl)-sulfonyn-1H-Pyrrolor[2,3-bi]pyridin-1-
yr]ethylamine dihydrochloride

Using essentially the same procedures described hereinabove and employing
3-iodo-1H-pyrrolo[2,3-b]pyridine and 3-chlorobenzenethiol as starting materials, the
title product is obtained as a white solid, mp 203-206°C, characterized by mass
spectral and HNMR analyses.
EXAMPLES 13-30
Preparation of N-N-Dimethvl-N-(2-{3-[(substituted phenyl)teulfonyn-1H-
pyrrolo[2,3-b]pyridin-1-yl}ethyftamlnehvdrochloride

Using essentially the same procedures described in Examples 4,5, or 6,
hereinabove or using the method described by J. Alvarez-Builla, et ai, Synthetic

Communications, (1991) 21(4), 535-544, and employing the appropriate 3-
(substituted sulfonyl)-1H-pyrrolol2,3-b]pyridine substrate and the desired
haloalkylamine, the products shown in Table I are obtained and identified by mass
spectral and HNMR analyses.




EXAMPLE 31
Preparation of N,N-D1methyl-N-[2-(1H-pyrrolo[2,3-b]pyridin-1-yltethynamine

A stirred solution of 1 H-pyrrolo[2,3-b]pyridine (5.00 g, 42.3 mmol) in DMF at
ambient temperature is treated with 95% sodium hydride in oil (3.78 g, 150 mmol).
After gas evolution subsides, the reaction mixture is treated with 2-(dimethylamino)-
ethyl chloride hydrochloride (6.40 g, 44.4 mmol), stirred for 16 h and concentrated in
vacuo. The resultant residue is partitioned between EtOAc and water. The organic
phase is separated, dried over MgSO4 and concentrated in vacuo to afford the title
compound as an oil, 6.50 g (81% yield), identified by HNMR and mass spectral
analyses.
EXAMPLE 32
Preparation of N.N-Dlmethvi N-[243-[(3-fluorophenynsulfonyn-1H-pyrrolor[2,3-
bipyridin-1-yl}ethyl)amine Dihydrochloride

A stirred solution of N,N-dimethyl-N-[2-(1H-pyrrolo[2,3-b]pyridin-1-
yl)ethyl]amine (1.66 g, 8.8 mmol) in nitrobenzene is treated with 3-

fluorophenylsutfonyl chloride (1.88 g, 9.7 mmol) under nitrogen, followed by silver
trifluoromethylsulfonate (2.94 g, 11.4 mmol), heated to 100°C for 22 h, cooled and
filtered through a cotton plug. The filtrate is treated with water and saturated
aqueous NaHCO3 and extracted with CH2CW The extracts are combined, dried over
MgSO4 and concentrated in vacua. The resultant residue is chromatographed eluting
with 2:98 concentrated NhUOH-.ethanol, to afford the free amine of the title compound
as a viscous oil which solidifies (1.25 g, 41%). The free amine is dissolved in warm
ethanol, treated with 4M HCI in dioxane and filtered. The filtercake is dried to give
the title product as a pale yellow solid, 1.07 g (29% yield), mp 191-192°C, identified
by mass spectral and HNMR analyses.
Preparation of N-{[2-(3-Arylsulfonyl)-1H-Dyrrolor[2,3-bi]pyriciin-1-ynethyl]amine
Deriyatives

Using essentially the same procedure described hereinabove and employing
the appropriately N1-substituted 1H-pyrrolo[2,3-b]pyridine substrate and the desired
arylsulfonyl chloride, the compounds shown on Table II are obtained and
characterized by mass spectral and HNMR analyses.





Preparation of N-(2-{3-[(3-Chlorophenyl)sulfonyn-1H-pyrrolo[2,3-bi]pyridin-1-
ynethyl)-N-methylamine Hydrochloride

A stirred solution under nitrogen of N-(2-{3-[(3-chlorophenyl)sulfonyl]-1H-
pyrrolo[2,3-b]pyridin-1-yl}ethyl)-N,N-dimethylamine (0.540 g, 1.49 mmol) in 1,2-
dichioroethane is treated with 1-chloroethyl chloroformate (0.40 mL, 3.7 mmol),
heated at reflux temperature for 2 h cooled, and concentrated in vacuo. The
resultant residue is treated with ethanol, heated at reflux temperature for 2 h and
concentrated in vacua. This resultant residue is chromatographed using 2:98
concentrated NhUOH-.ethanol as eluent to afford the free amine of the title product as
a semi-solid (311 mg, 60%). The free amine is dissolved in ethanol, treated with 4M
HCI in dioxane and filtered. The fittercake is dried to give the title product as a pale
yellow solid, 274 mg (48% yield), mp 263-265°C (dec.), identified by mass spectral
and HNMR analyses.

EXAMPLES 58-62
Preparation of N-{[2-(3-Aryisulfonyl)-1H-pyrroIor[2,3-bi]pyridin-1-yl]ethyl}amine
Deriyatives

Using essentially the same procedure described hereinabove and employing
the appropriate N-(N,N-disubstituted-aminoalkyl)-1H-pyrrolo[2,3-b]pyridine substrate,
the compounds shown on Table III are obtained and characterized by mass spectral
and HNMR analyses.


EXAMPLE 63
Preparation of 1-(1H-Pyrrolo[2,3-b]pyridin-1-ynacetonitrile

A stirred solution of 1H-pyrrolo[2,3-b]pyridine (5.06 g, 42.8 mmol) in DMF at
ambient temperature is treated portionwise with 95% sodium hydride (1.10 g, 43.5
mmol). After gas evolution subsides, the reaction mixture is treated with
bromoacetontoile (3.00 mL, 43.1 mmol), stirred for 16 h, and concentrated in vacuo.
The resultant residue is partitioned between EtOAc and water. The organic phase is
separated, dried over MgSO* and concentrated in vacuo. This residue is
chromatographed eluting with 1:3 EtOAchexanes to afford the title compound as a
waxy solid, mp 77-79° C, identified by HNMR and mass spectral analyses.
EXAMPLE 64

A stirred solution of 1-(1H-pyrrolo[2,3-b]pyridin-1-yl)acetonitrile (0.68 g, 4.33
mmol) in nitrobenzene is treated with benzenesutfonyl chloride (0.57 mL, 4.4 mmol)

and silver trifluoromethanesutfonate (1.50 g, 5.8 mmol), heated at 125°C for 16 h,
cooled and partitioned between saturated aqueous NaHCCb andCHgCfe. The organic
phase is dried over MgSO4 and concentrated in vacuo. The resultant residue is
chromatographed eluting initially with 1:4 EtOAc:hexanes and then with 12
EtOAcrhexanes to afford the title compound as a tan solid, 0.70 g (54% yield),
mp 140-142°C, identified by mass spectral and HNMR analyses.
EXAMPLE 65
Preparation of 2-r3-(phenvlsulfonvlV1H-pviTolof2.3-biDVridln-1-vllethvlamine

A portion of 1-[3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-1-yl]acetonitrile
(0.30 g, 1.00 mmol) is treated with 1.0M borane in tetrahydrofuran (THF) (4.0 mL,
4.0 mmol) in 0.5 mL portions at ambient temperature, stirred for 16h, treated with 2.0
M HCI (15 mL), heated at 100°C for 2 h, cooled in an ice bath, treated wrth.2.5 M
aqueous NaOH, and extracted with ether. The extracts are combined, dried over
MgSO4 and concentrated in vacuo to afford the title compound as an oil, 0.180 g
(60% yield), identified by HNMR and mass spectral analyses.

EXAMPLES 66-68
Preparation of [3-(Arylsultonyl)-1H-pyrrolo[2,3-b]pyridin-1-ynalkylamine
Deriyatives

Using essentially the same procedures described in Examples 64 and 65
hereinabove and employing the appropriate 3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridine-
1-acetonitrile substrate, the compounds shown on Table IV are obtained and
characterized by mass spectral and HNMR analyses.


EXAMPLE 69
Preparation of 4-Nitro-3-[(Dhenylsulfonyl)methyn-pyridine-N-oxide

Adapting the procedure of Makosza, et al, Liebigs Ann. Chem., 1984, 8-14, a
stirred mixture of 4-nirtro-pyridine-N-oxide (1.40 g, 10.0 mmol) and
chloromethylphenylsulfone (1.92 g, 10.0 mmol) in DMSO (25 mL) in a cold water
bath is treated with a solution of KOH (4.0 g, 71 mmol) in DMSO, stirred for 45 min,
poured into 1.0 M hydrochloric acid and water and extracted with CH2CI2. The
aqueous phase is filtered and the filtercake is dried in vacuo to afford the title
compound, 120 g (41% yield). The organic extracts are combined, dried over
MgSO4 and concentrated in vacuo. The resultant wet solid is heated in boiling
ethanol:water (4:1) and filtered. The filtrate is cooled, concentrated and filtered. This
filtercake is dried in vacuo to afford an additional portion of the title compound, 0.967
g (74% total yield), mp 219-220°C, identified by mass spectral and HNMR analyses.
EXAMPLE 70
Preparation of 3-phenylsulfonyl-1H-pyrrolor[3,2-c]pyridine

A mixture of 4-nitro-3-[(phenylsulfonyl)methyl]-pyridine-N-oxide (1.43 g, 4.90
mmol) in methanol is heated with ammonium formate (1.54 g, 24.5 mmol) and 10%
palladium on carbon (0.50 g) at 50°C for 24 h, treated with additional ammonium

formate (0.63 g, 10 mmol), heated at reflux for 30 h, cooled and filtered. The filtrate
is concentrated in vacuo. The resultant residue is suspended in ethanohwater and
filtered to remove residual catalyst This filtrate is concentrated, cooled and filtered.
The fittercake is dried to afford a tan solid (0.60 g). This solid (0.55 g) is admixed
with triethyiorthoformate (1.84 mL, 11.1 mmol), para-toluenesulfonic acid (pTsOH)
monohydrate (42 mg, 0.22 mmol) and 1,2-dichloroethane, heated at reflux for 7 h
and concentrated in vacuo. The resultant residue is dispersed in tetrahydrof uran,
treated with 1.0 M KO-t-Bu in tetrahydrof uran (3.1 mL, 3.1 mmol), stirred for 2 h,
treated with saturated aqueous NH4CI and water and extracted with CH2CI2. The
extracts are combined, dried over MgSO4 and concentrated in vacuo. The resultant
orange solid residue is chromatographed eluting initially with EtOAc, then with 10:90
ethanol:EtOAc to afford the title compound as an off-white solid, 330 mg (58% yield),
mp 261-263°C, identified by mass spectral and HNMR analyses.
EXAMPLE 71
Preparation of N,N-Dimethy-1-N-{2-{3-(phenylsulfonyl)-1H-Dyrrolor[3,2-c]pyridin-
i-vl]ethyflamine dihydrochloride

Using essentially the same procedure described in Example 6 hereinabove
and employing 3-phenylsulfonyl-1H-pym>lo[3f2-c]pyridine, ambient reaction
temperatures and a 24 h reaction time period, the title compound is obtained as an
off-white solid, mp 255-257° C, identified by mass spectral and HNMR analyses.

EXAMPLE 72
Preparation of 6-Methoxy-3-nitro-2-r(phenylsulfonynmethyn-pyridine

A1M KOt-Bu solution in tetrahydrofuran (50 mL, 50 mmol) is cooled to
-40°C, treated portion-wise with a solution of chloromethyl phenyl sulfone (4.39 g,
23.0 mmol) and then with a solution of 2-methoxy-5-nitropyridine (3.55 g, 23.0 mmol)
in tetrahydrofuran, stirred for 45 min at -40°C, treated with glacial acetic acid (3.0 g,
50 mmol) and filtered. The filtercake is air-dried to give the title compound as a tan
solid, 5.70 g (80% yield), mp 147-149°C, identified by mass spectral and HNMR
analyses.
Preparation of 3-Amino-6-tnethoxy-2-[1(phenylsulfonynmethyn-pyridine

A stirred mixture of 6-methoxy-3-nitro-2-[(phenylsuifonyf)methyf]-pyridine
(6.17 g, 20.0 mmol) in methanol and concentrated HCI (50 mL) is treated with thin
strips of tin foil (10.0 g, 842 mmol), heated at 60°C for 20 h, and filtered hot The
filtrate is poured over ice and 2.5N aqueous NaOH, stirred for 0.5 h and filtered. The
filtercake is air-dried to afford the title compound as a white solid 5.26 g (94%) yield,
identified by mass spectral and HNMR analyses.

EXAMPLE 74
Preparation of N-{6-Methoxy-r2-(Dhenylsulfonynmethyn-pyridin-3-yl]-
formlmidtc Acid Ethyl Ester

A stirred mixture of 3-amino-6-methoxy-2-[(phenylsulfonyl)methyl]-pyridine
(2.40 g, 8.62 mmol) in triethyl orthoformate (20 ml_) and p-toluenesuifonic acid
(pTsOH) monohydrate (0.15 g, 0.788 mmol) is heated at 155°C for 48 h and
concentrated in vacua. The resultant residue is diluted with hexanes and filtered to
give the title product as a tan solid, 2.54 g (88% yield), identified by mass spectral
and HNMR analyses.
EXAMPLE 75
Preparation of 5-Methoxv^3-phenvlsulfonvl-1H-Dvrrolor3.2-biDvridine

A stirred solution of N-{6-methoxy-[2-(phenylsulfonyl)methyi]-pyridin-3-yl}-
formimidic add ethyl ester (2.54 g, 7.60 mmol) in DMSO is treated with powdered
KOt-Bu (4.50 g, 38.0 mmol), stirred at ambient temperature for 4 h, treated with 10%
aqueous NH4CI and extracted with EtOAc. The extracts are combined, dried over
MgSO4and concentrated in vacuo. The resultant residue is recrystallized from

EtOAc to afford the title compound as a tan solid, 0.42 g (19% yield), mp 223-225°C,
identified by mass spectral and HNMR analyses.
EXAMPLE 76
Preparation of N.N-Plmethvl-N-l2-r3-(Dhenylsulfonyl-1H-Dyrrolor[3,2-b]pyridin-
1-yl]nethyl)amine Dihydrochloride

A stirred solution of 5-methoxy-3-phenylsulfonyM H-pyrrolo[3,2-b]pyridine
(0.288 g, 1.00 mmol) in dry dimethyl formamide is treated with 95% NaH (0.075 g.
2.97 mmol), stirred at ambient temperature until gas evolution subsides, treated with
2-(dimethylamino)ethylchlorfde hydrochloride (0200 g, 1.39 mmol), stirred for 16 h at
80°C, concentrated in vacuo and partitioned between water and EtOAc. The organic
phase is dried over MgSO4and concentrated in vacuo. The resultant residue Is
chromatographed eluting with EtOAc, then 1:9 CH3OH:EtOAc, to obtain a semi-solid
(0.216 g, 60% yield of the free amine). The semi-solid is dissolved in ethanol and
treated with 4N HCI in dioxane and filtered. The fittercake is dried and triturated with
ether to afford the title compound as a white solid, 0.19 g, mp 212-214°C, identified
by mass spectral and HNMR analyses.

EXAMPLE 77
Preparation of N,N-Dimethyl-N-(243-[(3-fluorophenyl)sulfonyl)-1H-pyrrolor[3,2-
b]pyridin-1-ynethylteminedihydrochloride

Using essentially the same procedures described in Examples 6,8,9 and 10
hereinabove and employing 1-H-pyrrolo[3,2-b]pyridine as the starting material, the
title compound is obtained as a white solid, mp 163-165°C, identified by mass
spectral and HNMR analyses.
EXAMPLES 78-81
Preparation of N-[2-[3-(Arylsulfonyl)-1H-pyrrolo[3,2-b]pyridin-1-ynethyllamine
Deriyatives

Using essentially the same procedures described in Examples 72-76
hereinabove and employing the appropriately substituted nitrobenzene starting
material and arylsulfonyl chloride and chloroethylamine reagents, the compounds
shown on Table V are obtained and identified by mass spectral and HNMR analyses



EXAMPLE 82
Comparative Evaluation of 5-HT6 Binding Affinity of Test Compounds
The affinity of test compounds for the serotonin 5-HT6 receptor is evaluated
in the following manner. Cultured Hela cells expressing human cloned 5-HT6
receptors are harvested and centrifuged at tow speed (1,000 x g) for 10.0 min to
remove the culture media. The harvested cells are suspended in half volume of fresh
physiological phosphate buffered saline solution and recentrifuged at the same
speed. This operation is repeated. The collected cells are then homogenized in ten
volumes of 50 mM Tris.HCI (pH 7.4) and 0.5 mM EDTA. The homogenate is
centrifuged at 40,000 x g for 30.0 min and the precipitate is collected. The obtained
pellet is resuspended in 10 volumes of Tris.HCI buffer and recentrifuged at the same
speed. The final pellet is suspended in a small volume of Tris.HCI buffer and the
tissue protein content is determined in aliquots of 10-25 /A volumes. Bovine Serum

Albumin is used as the standard in the protein determination according to the method
described in Lowry et al., J. Biol. Chem., 193:265 (1951). The volume of the
suspended cell membranes is adjusted to give a tissue protein concentration of 1.0
mg/ml of suspension. The prepared membrane suspension (10 times concentrated)
is aliquoted in 1.0 ml volumes and stored at -70° C until used in subsequent binding
experiments.
Binding experiments are performed in a 96 well microtiter plate format, in a
total volume of 200 µI. To each well is added the following mixture: 80.0 µI of
incubation buffer made in 50 mM Tris.HCI buffer (pH 7.4) containing 10.0 mM MgCfe
and 0.5 mM EDTA and 20 µA of [3H]-LSD (SA, 86.0 Ci/mmol, available from
Amersham Life Science), 3.0 nM. The dissociation constant, Ko of the [3H]LSD at the
human serotonin 5-HT6 receptor is 2.9 nM, as determined by saturation binding with
increasing concentrations of [3H]LSD. The reaction is initiated by the final addition of
100.0 µI of tissue suspension. Nonspecific binding is measured in the presence of
10.0 µM methiothepin. The test compounds are added in 20.0 µI volume.
The reaction is allowed to proceed in the dark for 120 min at room
temperature, at which time, the bound ligand-receptor complex is filtered off on a 96
well unifilter with a Packard Filtermate* 196 Harvester. The bound complex caught
on the filter disk is allowed to air dry and the radioactivity is measured in a Packard
TopCount* equipped with six photomultiplier detectors, after the addition of 40.0µl
Microscint*-20 scintillant to each shallow well. The unifilter plate is heat-sealed and
counted in a PackardTopCount* with a tritium efficiency of 31.0%.
Specific binding to the 5-HT6 receptor is defined as the total radioactivity
bound less the amount bound in the presence of 10.0µM unlabeled methiothepin.
Binding in the presence of varying concentrations of test compound is expressed as
a percentage of specific binding in the absence of test compound. The results are
plotted as log % bound versus log concentration of test compound. Nonlinear
regression analysis of data points with a computer assisted program Prism® yielded
both the ICso and the Ki values of test compounds with 95% confidence limits. A
linear regression line of data points is plotted, from which the IG50 value is
determined and the Ki value is determined based upon the following equation:
K1=IC50/(1+L/KD)

where L is the concentration of the radioactive ligand used and KD is the dissociation
constant of the ligand for the receptor, both expressed in nM.
Using this assay, the following Ki values are determined and compared to
those values obtained by representative compounds known to demonstrate binding
to the 5-HT6 receptor. The data are shown in Table VI, below.





As can be seen from the results set forth above, the compounds of the
present invention demonstrate significant affinity for the 5-HT6 receptor.

WE CLAIM:
1. 1 -(Aminoalkyl)-3-sulfonylazaindole compounds of formula I

wherein
W is N or CR7;
X is N or CR8;
Y is N or CR9;
Z is N or CR10 with the proviso that at least one and no more than two of W, X,
Y and Z must be N;
n is an integer of 2, 3, 4 or 5;
R1 is an optionally substituted C1-C6alkyl, C3-C7cycloalkyl, aryl, or heteroaryl
group or an optionally substituted 8- to 13-membered bicyclic or tricyclic
ring system having a N atom at the bridgehead and optionally containing 1,
2 or 3 additional heteroatoms selected from N, O or S;
R2 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, C3-C7cycloalkyl, aryl or
heteroaryl group each optionally substituted;
R3 and R4 are each independently H or an optionally substituted C1-C6alkyl
group;
R5 and R6 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl,
C3-C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each
optionally substituted , or R5 and R6 may be taken together with the atom
to which they are attached to form an optionally substituted 5- to 8-
membered ring optionally containing an additional heteroatom selected
fromO,NR11 or SOm;

R7, R8, R9 and R10 are independently H, halogen, CN, OCO2R12, CO2R13,
CONR14R15, SOpR16, NR17R18, OR19, COR20, or a C1-C6alkyl, C2-
C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, aryl or
heteroaryl group each optionally substituted;
R11, R12, R13, R16, R19 and R20 are each independently H or a C1-C6alkyl, C2-
C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or
heteroaryl group each optionally substituted;
R14 and R15 are each independently H or an optionally substituted C1-C6alkyl
group or R14 and R15 may be taken together with the atom to which they
are attached to form a 5- to 7-membered ring optionally containing
another heteroatom selected from O, NR22 or S;
R17 and R18 are each independently H or an optionally substituted C1-C4alkyl
group or R17 and R18 may be taken together with the atom to which they
are attached to form a 5- to 7-membered ring optionally containing
another heteroatom selected from O, NR21 or SOX;
R21 and R22 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C3-
C7cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally
substituted; and
m, p and x are each independently 0 or an integer of 1 or 2; or a stereoisomer
thereof or a pharmaceutically acceptable salt thereof;
wherein the terms have the meanings below:
"cycloheteroalkyl" denotes a 5-7 membered ring system containing 1 or 2
heteroatoms, which may be the same or different, selected from nitrogen, oxygen and
sulfur and optionally containing one double bond;
"heteroaryl" denotes a five to ten membered aromatic ring system containing 1, 2
or 3 heteroatoms, which may be the same or different, selected from N, O or S;
"aryl" denotes a carbocyclic aromatic ring system having 6-14 carbon atoms;
"optionally substituted" means optional substitution by one to three of the
following substituents: halogen, nitro, cyano, hydroxyl, C1-C6alkyl, C1-C6haloalkyl, C1-
C6alkoxy, C1-C6haloalkoxy, amino, C1-C6alkylamino, di C1-C6alkylamino, formyl, (C1-
C6alkoxy)carbonyl, carboxyl, C2-7alkanoyl, C1-C6alkylthio, C1-C6alkylsuphinyl, C1-
C6alkylsulphonyl, carbamoyl, C1-C6alkylamido, phenyl, phenoxy, benzyl, benzyloxy,
heteroaryl, cycloheteroalkyl or cycloalkyl groups.

2. A compound as claimed in claim 1 wherein W or Z is N.
3. A compound as claimed in claim 1 or claim 2 wherein n is 2.
4. A compound as claimed in any one of claims 1 to 3 wherein Ri is an
optionally substituted phenyl, naphthyl or imidazothiazolyl group.
5. A compound as claimed in claim 4 wherein Ri is phenyl optionally
substituted with halogen or 1-naphthyl or 6-chloroimidazo[l,2-b][l,3]
thiazol-5-yl.
6. A compound as claimed in any one of claims 1 to 5 wherein W is CR7; X
is CR8; and Y is CR9.
7. A compound as claimed in any one of claims 1 to 6 wherein X is CRs; Y
is CR9; and Z is CR10.
8. A compound as claimed in any one of claims 1 to 7 wherein Rs and R6
are each independently H or C1-C3alkyl.
9. A compound as claimed in any one of claims 1 to 8 wherein R3 and R4 are
H.
10. A compound as claimed in any one of claims 1 to 9 wherein R2 is H.
11. A compound as claimed in claim 1 which is one of the following:
2-[3-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-l-yl]ethylamine;
2-[3-(phenylsulfonyl)-lH-pyrrolo[2,3-c]pyridin-l-yl]ethylamine;
2-[3-(phenylsulfonyl)-lH-pyrrolo[3,2-c]pyridin-l-yl]ethylamine;
2- { 3 - [(4-fluorophenyl)sulfonyl] -1 H-pyrrolo [3,2-b]pyridin-1 -yl} ethylamine;
2-{3-[(4-methylphenyl)sulfonyl]-lH-pyrrolo[2,3-b]pyridin-l-yl}ethylamine;
2-[3-(naphth-l-yl)sulfonyl)-lH-pyrrolo[2,3-b]pyridin-l-yl]ethylamine;

2- {3-[(6-chloro-imidazo[2, l-b][l ,3]thiazol-5-yl)sulfonyl] -1 H-pyrrolo[2,3-b]pyridin-1 -
yl}ethylamine;
2-{3-[(3-chlorophenyl)sulfonyl]-lH-pyrrolo[2,3-b]pyridin-l-yl}ethylamine;
2- {3 - [(2-chlorophenyl)sulfonyl] -1 H-pyrrolo[2,3 -c]pyridin-1 -yl} ethylamine;
2-{3-[(3-methoxyphenyl)sulfonyl]-lH-pyrrolo[3,2-c]pyridin-l-yl}ethylamine;
2-{3-[(4-fluorophenyl)sulfonyl]-lH-pyrrolo[3,2-b]pyridin-l-yl}ethylamine;
N,N-dimethyl-N-(2-{3-[(3-fluorophenyl)sulfonyl]-lH-pyrrolo[2,3-b]pyridin-l-yl}ethyl)
amine;
N,N-dimethyl-N-{2-[3-(naphth-l-ylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-l-yl]ethyl}
amine;
N,N-dimethyl-N-(2- {3-[(6-chloroimidazo[ 1,2-b] [1,3]thiazol-5-yl)sulfonyl]- lH-pyrrolo
[2,3-b]pyridin-l-yl}ethyl)amine;
N,N-dimethyl-N-(2-{3-[(3-chlorophenyl)sulfonyl]-lH-pyrrolo[2,3-b]pyridine-l-yl}
ethyl)amine;
3-[3-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-l-yl]propan-l-amine;
3-[3-(phenylsulfonyl)-lH-pyrrolo[2,3-c]pyridin-l-yl]propan-l-amine;
3-[3-(phenylsulfonyl)-lH-pyrrolo[3,2-c]pyridin-l-yl]propan-l-amine;
3.{3.[(4-fluorophenyl)sulfonyl]-lH-pyrrolo[3,2-b]pyridin-l-yl}propan-l-amine;
2-{6-chloro-3-[(3-chlorophenyl)sulfonyl]-lH-pyrrolo[2,3-b]pyridin-l-yl}ethylamine;
2-{7-chioro-34(2-chlorophenyl)sulfonyl]-lH-pyrrolo[2,3-c]pyridin-l-yl}ethylamine;
4-{3-[(3-methoxyphenyl)sulfonyl]-lH-pyrrolo[3,2-c]pyridin-l-yl}butan-l-amine;
4-{3-[(4-fluorophenyl)sulfonyl]-lH-pyrrolo[3,2-b]pyridin-l-yl}butan-l-amine;
N,N-dimethyl-N-{2-[3-(phenylsulfonyl)-lH-pyrrolo[2,3-c]pyridin-l-yl]ethyl} amine;
N,N-dimethyl-N-{2-[3-(phenylsulfonyl)-lH-pyrroio[3,2-c]pyridin-l-yl]ethyl}amine;
N,N-dimethyl-N-{2-[3-(thien-2-yl)-lH-pyrrolo[2,3-b]pyridin-l-yl]ethyl}amine;
N,N-dimethyl-N-{2-[3-(naphth-l-yl)-lH-pyrrolo[2,3-b]pyridin-l-yl]ethyl}amine;
N,N-dimethyl-N-(2-{3-[(4-fluorophenyl)sulfonyl]-lH-pyrrolo[3,2-b]pyridin-l-yl}ethyl)
amine;
N-methyl-N-(2-{3-[(3-chlorophenyl)sulfonyl]-lH-pyrrolo[2,3-b]pyridin-l-yl}ethyl)
amine;

N-methyl-N-(2-{3-[(3-fluorophenyl)sulfonyl]-lH-pyrrolo[2,3-b]pyridin-l-yl}ethyl)
amine;
N-methyl-N-{2-[3-(naphth-1 -ylsulfonyl)- lH-pyrrolo[2,3-b]pyridin-1 -yl]ethyl} amine;
N-methyl-N-(2-{3-[(6-chloroimidazo[l,2-bl[l,3]thiazol-5-yl)sulfonyl]-lH-pyrrolo[2,3-
b]pyridin-1 -yl} ethyl)amine;
N-methyl-N-(2-{3-[(2-chlorophenyl)sulfonyl]-lH-pyrrolo[2,3-c]pyridin-l-yl}ethyl)
amine;
N-methyl-N-(2-{3-[(3-methoxyphenyl)sulfonyl]-1 H-pyrrolo[3,2-c]pyridin-1 -yl}ethyl)
amine;
N-benzyl-N-(2-{3-[(4-fluorophenyi)sulfonyl]-lH-pyrrolo[3,2-b]pyridin-l-yl}ethyl)
amine;
N,N-dibenzyl-3-[3-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-l-yl]propan-l-amine;
3-[3-(phenylsulfonyl)- lH-pyrrolo[2,3-c]pyridin-1 -yljpropan-1 -amine;
3 -[3 -(phenylsulfonyl)-1 H-pyrrolo[3,2-c]pyridin-1 -yljpropan-1 -amine;
the stereoisomers thereof; and the pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition which comprises a pharmaceutically
acceptable carrier and a compound of formula I as claimed in any one of
claims 1 to 11 or a stereoisomer thereof, or a pharmaceutically acceptable
salt thereof.
13. A composition as claimed in claim 12 for the treatment of a disorder of
the central nervous system related to or affected by the 5-HT6 receptor in
a patient in need thereof which comprises providing to said patient a
therapeutically effective amount of a compound of formula I as claimed
in any one of claims 1 to 11 or a stereoisomer thereof, or a
pharmaceutically acceptable salt thereof.
14. A composition as claimed in claim 13 wherein said disorder is a motor
disorder, anxiety disorder or cognitive disorder.

15. A composition as claimed in claim 13 wherein said disorder is a
neurodegenerative disorder.
16. A composition as claimed in claim 14 wherein said disorder is attention
deficit disorder or obsessive compulsive disorder.
17. A composition as claimed in claim 15 wherein said disorder is stroke or
head trauma.
18. A process for the preparation of a compound of formula I as claimed in
claim 1 or a stereoisomer thereof, or a pharmaceutically acceptable salt
thereof, which process comprises one of the following:
a) reacting a compound of formula II

wherein W, X, Y, Z, Ri and R2 are as described hereinabove with a haloalkylamine of
formula III
Hal - (CR3R4)n-NR5R6
(III)
wherein Hal represents Cl, Br or I and R3, R4, R5, Re and n are as described hereinabove
in the presence of a base to give a compound of formula I;
or
b) reacting a compound of formula (V)


wherein W, X, Y, Z, Ri, R3, R4 and n are as defined in claim 1 and Hal is a halogen, with
a compound of formula
HNR5R6
wherein R5 and R6 are as defined in claim 1 to give a compound of formula I;
or
c) sulphonylating a compound of formula XVI:

wherein W, X, Y, Z, R3, R4, R5, R6 and n are as defined in claim 1, with a compound of
formula:
CISO2R1
wherein R1 is as defined in claim 1 to give a compound of formula I;
or
d) reducing a compound of formula XX:


wherein W, X, Y, Z, R1, R3, R4 and n are as defined in claim 1, to give a corresponding
compound of formula I wherein R5 and R6 are both hydrogen;
or
e) reacting a compound of formula

wherein W, X, Y, Z, R1, R2, R3, R4, n and m are as defined in claim l,with hydrazine to
give a corresponding compound of formula I wherein R5 and R6 are both hydrogen;
or
f) converting a basic compound of formula I to a pharmaceutically acceptable salt
thereof or vice versa.
The present invention provides a
compound of formula (I) and the use thereof for
the therapeutic treatment of disorders relating to or
affected by the 5-HT6 receptor.

Documents:

1785-kolnp-2004-granted-abstract.pdf

1785-kolnp-2004-granted-assignment.pdf

1785-kolnp-2004-granted-claims.pdf

1785-kolnp-2004-granted-correspondence.pdf

1785-kolnp-2004-granted-description (complete).pdf

1785-kolnp-2004-granted-examination report.pdf

1785-kolnp-2004-granted-form 1.pdf

1785-kolnp-2004-granted-form 18.pdf

1785-kolnp-2004-granted-form 3.pdf

1785-kolnp-2004-granted-form 5.pdf

1785-kolnp-2004-granted-gpa.pdf

1785-kolnp-2004-granted-letter patent.pdf

1785-kolnp-2004-granted-reply to examination report.pdf

1785-kolnp-2004-granted-specification.pdf


Patent Number 213806
Indian Patent Application Number 01785/KOLNP/2004
PG Journal Number 03/2008
Publication Date 18-Jan-2008
Grant Date 16-Jan-2008
Date of Filing 24-Nov-2004
Name of Patentee WYETH
Applicant Address FIVE GIRALDA FARMS, MADISON, NJ 07940
Inventors:
# Inventor's Name Inventor's Address
1 BERNOTAS RONALD CHARLES 106 WICKLOW WAY, BRIDGEWATER, NJ 08807
2 LENICEK STEVEN EDWARD 47-08 QUAIL RIDGE, PLAINSBORO, NJ 08536
3 ANTANE SCHUYLER A 56 LILLIE STREET, PRINCETON JUNCTION, NJ 08550
PCT International Classification Number C 07 D 471/04
PCT International Application Number PCT/US03/17466
PCT International Filing date 2003-06-03
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/385, 502 2002-06-04 U.S.A.